Cancer clinical trials in the region Normandie
254 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lymphoma
#NCT06284122
#2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min
< 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant
Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3
Kidney cancer
#NCT07227402
#2024-517136-21-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Endometrial cancer
#NCT07022483
#2024-519444-33-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
POLE
5 recruiting sites
Daiichi Sankyo
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Multiple myeloma
#NCT06918002
#2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome
Phase 3
Thyroid and adrenal gland cancer
#NCT04290663
#2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3
Head and neck cancer
#NCT07264075
#2025-522996-27-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
6 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Small intestine and appendix cancer
#NCT06878664
#2024-517921-14-00
Required histologic types
Jejunum cancer
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
3 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Head and neck cancer
#NCT06496178
#2023-510322-32-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
15 recruiting sites
Merus